3 results
Primary Objective: The primary objective for this study is to compare the efficacy of ABP 215 with bevacizumab.Secondary Objective(s): The secondary objectives are to assess the safety and immunogenicity of ABP 215 compared with bevacizumab.
Primary:* To demonstrate non-inferiority between the level of agreement in diagnosis (i.e. patient classification of normal, mild/moderate or severe ischemic disease based on the number of reversible perfusion segments) between sequential adenosine…
In this study, we will evaluate a possible interaction between IMU-935 and midazolam. We will do this by investigating the effect of IMU-935 on how quickly and to what extent midazolam is absorbed, transported, and eliminated from the body. In…